Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients.

about

Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients.

Item

http://www.wikidata.org/entity/Q41550939

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Improving circulating tumor ce ...... e chemotherapy mCRPC patients.

@en

type

Item

label

Improving circulating tumor ce ...... e chemotherapy mCRPC patients.

@en

prefLabel

Improving circulating tumor ce ...... e chemotherapy mCRPC patients.

@en

P1476

Improving circulating tumor ce ...... e chemotherapy mCRPC patients.

@en

P2093

Alicia Abalo

http://www.w3.org/2001/XMLSchema#string

Helena Casas

http://www.w3.org/2001/XMLSchema#string

Laura Muinelo-Romay

http://www.w3.org/2001/XMLSchema#string

Luis León-Mateos

http://www.w3.org/2001/XMLSchema#string

Manuel Abreu

http://www.w3.org/2001/XMLSchema#string

Miguel Abal

http://www.w3.org/2001/XMLSchema#string

Rafael López

http://www.w3.org/2001/XMLSchema#string

Urbano Anido

http://www.w3.org/2001/XMLSchema#string

P2860

Rab7: roles in membrane trafficking and disease

Stem-like features of cancer cells on their way to metastasis

Role of the Androgen-Androgen Receptor Axis in the Treatment Resistance of Advanced Prostate Cancer: From Androgen-Dependent to Castration Resistant and Further

Insights into Chemoresistance of Prostate Cancer

Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer

Using circulating tumor cells to inform on prostate cancer biology and clinical utility

Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.

P304

54708-54721

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.18025

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

María Vieito

A Gómez-Tato

P577

2017-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28903376

http://www.w3.org/2001/XMLSchema#string

P932

5589615

http://www.w3.org/2001/XMLSchema#string